Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 50, 2641-2645, May 1, 1990]
© 1990 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kitada, M.
Right arrow Articles by Kamataki, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kitada, M.
Right arrow Articles by Kamataki, T.

Metabolic Activation of Aflatoxin B1 and 2-Amino-3-methylimidazo[4,5-f]-quinoline by Human Adult and Fetal Livers1

Mitsukazu Kitada2, Masaki Taneda, Kazuhide Ohta, Kazuo Nagashima, Koshiro Itahashi and Tetsuya Kamataki

Division of Analytical Biochemistry, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo 060, Japan, and Department of Pathology, Faculty of Medicine, Hokkaido University [K. N.], Kawasaki Seitetsu Hospital, Chiba 280, Japan [K. I.]

The mutagenic activation of promutagens by human adult and fetal livers was investigated using the umu test system. Among the promutagens studied, aflatoxin B1 (AFB1) and 2-amino-3-methyl-imidazo[4,5-f] quinoline (IQ) were efficiently activated to mutagens by both adult and fetal livers. 7,8-Benzoflavone inhibited the activation of IQ by fetal livers, but the inhibition observed in fetal livers was much less than that observed in adult livers. Antibodies to P450HM1 (P450111A4) and P450HFLa markedly inhibited the activation of AFB1 by adult and fetal livers, respectively. The formation of genotoxic product(s) from IQ in human adult livers was almost completely inhibited by anti-P448H (P4501A2) antibodies but not by anti-P450HM1 antibodies, whereas that in fetal livers was inhibited by both anti-P450HFLa and anti-P450IA2 antibodies. P450HFLa catalyzed the mutagenic activation of both AFB1 and IQ in a reconstituted system. On the contrary, P450HM1 catalyzed the mutagenic activation of AFB1 but not IQ. A preparation of cytochrome P450 partially purified from human fetal livers and cross-reactive with anti-P450IA2 antibodies was found to be active for mutagenic activation of IQ in a reconstituted system.

These results indicate that P450HFLa and P450HM1 are mainly involved in the genotoxic product formation from AFB1 in fetal and adult livers, respectively, and that the metabolic activation of IQ in fetal livers is catalyzed by two forms of cytochrome P450, P450HFLa, and cytochrome P450 immunochemically related to P450IA2 but that in adult livers it is mainly catalyzed by cytochrome P450 related to P450IA2.

1 This work was partly supported by a Grant-in-Aid for Cancer Research from the Ministry of Education Science and Culture of Japan and the Uehara Memorial Foundation.

2 To whom requests for reprints should be addressed.

Received 9/13/89. Revised 1/ 4/90.


This article has been cited by other articles:


Home page
MutagenesisHome page
A. Hakura, H. Shimada, M. Nakajima, H. Sui, S. Kitamoto, S. Suzuki, and T. Satoh
Salmonella/human S9 mutagenicity test: a collaborative study with 58 compounds
Mutagenesis, May 1, 2005; 20(3): 217 - 228.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
G. Ginsberg, D. Hattis, R. Miller, and B. Sonawane
Pediatric Pharmacokinetic Data: Implications for Environmental Risk Assessment for Children
Pediatrics, April 1, 2004; 113(4/S1): 973 - 983.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
B. Sinués, M. A. Sáenz, J. Lanuza, M. L. Bernal, A. Fanlo, J. L. Juste, and E. Mayayo
Five Caffeine Metabolite Ratios to Measure Tobacco-induced CYP1A2 Activity and Their Relationships with Urinary Mutagenicity and Urine Flow
Cancer Epidemiol. Biomarkers Prev., February 1, 1999; 8(2): 159 - 166.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1990 by the American Association for Cancer Research.